ADVENTRX submits NDA for Exelbine to FDA ADVENTRX Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application to the U.S. Food and Medication Administration because of its product candidate ANX-530 , or Exelbine. ‘Our Exelbine submission includes twelve months of site-specific stability data from our meant commercial manufacturer, which fulfills a request communicated to us by the FDA previously this year. Culley, CEO of ADVENTRX. Related StoriesAlnylam presents positive ongoing stage 2 open-label extension data for Patisiran and RevusiranAllergan settles patent litigation with Amneal linked to NAMENDA XR prolonged release capsulesHutchison MediPharma begins sulfatinib Phase I trial in USADVENTRX retains exceptional worldwide rights to Exelbine, other than in China, Hong Kong, Macau and Taiwan.The researchers suggest a deep tone of voice in a man is comparable to a peacock’s tail – it does not have any survival worth, but attracts the feminine of the species. It is testosterone which masculinizes the voice at puberty. Related StoriesProstate Cells Undergo 'Reprogramming' To Form Tumors, Study FindsStudy displays restoring testosterone production in men does not impact their fertilityNew assessment tool under development can help detect physical traits of Klinefelter syndromeThe researchers led by David Feinberg, assistant professor in the Department of Psychology, Neuroscience and Behaviour at McMaster University and Coren Apicella studied the Hadza tribe in Tanzania that have been chosen because their way of life reflects those of human beings thousands of years back.